Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP4396 in Advanced Solid Tumors With KRAS G12D Mutation
NCT06364696Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP4396 in solid tumor (2 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities at 21 days, Number of Participants with Adverse Events at 12 months and 1 more. Started Apr 2024; status: terminated.
02
Drugs
ASP4396
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06364696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364696.